Argenx

Argenx is a global immunology company specializing in the development of innovative therapies for severe autoimmune diseases and cancer. They leverage their proprietary antibody engineering technology to create novel treatments, with their lead product, efgartigimod, targeting autoimmune conditions like myasthenia gravis. Founded in 2008 in Belgium, argenx has rapidly grown through strategic partnerships and a strong pipeline of clinical trials. Their revenue model primarily revolves around product sales, milestone payments, and royalties from collaborations.

Recent Posts by Argenx

1-20 of 74